UK-based medical endowment Wellcome Trust is creating a £200m ($300m) investment company to invest in start-up biotechnology companies.
The company, temporarily called Sigma, will focus on UK and European transformational technologies with potential for high returns over at least a decade.
Nigel Keen, chairman of public technology companies in the healthcare and electronics industries, including Oxford Instruments, Laird, Bioquell and Deltex Medical, will be chairman of Sigma.
Martin Murphy (pictured), previously a partner at venture capital firm MVM Life Science…
